Dietary fiber supplementation and short chain fatty acids as immune regulators in COPD: a potential novel therapy to reduce airway inflammation in COPD.

Annalicia Vaughan0 个研究点目标入组 100 人开始时间: 2018年6月22日最近更新: 2020年10月19日

适应症

试验速览

暂无简介。

•Patients will have COPD as defined by the GOLD guidelines (chronic airflow limitation that is not fully reversible, with post-bronchodilator FEV1/FVC <70% and FEV1 <80% predicted). COPD patients will be former smokers of >10 pack-years, who are recruited during stability (>6 weeks since an exacerbation). Healthy participants will have self-reported good health, be free of any major medical conditions, and will be never smokers.

•Exclusion criteria will be use of any continuous prophylactic antibiotics or oral steroids in the past 3 months; current smoking; comorbid lung diseases (asthma, lung cancer, interstitial lung disease, bronchiectasis) that interfere with study outcomes; other comorbidities with established altered microbiome (including IBD, irritable bowel syndrome), and extreme dietary habits significantly impact on gut microbiome composition.

发起方

Annalicia Vaughan